ClinicalTrials.gg
RecruitingNCT06734221STAR-PAKUpdated Dec 16, 2024

STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femoro-Popliteal Lesions

An interventional study of Paclitaxel Coated Peripheral Angioplasty Balloon Catheter in Popliteal Artery Stenosis Above the Knee, Peripheral Artery Disease and Superficial Femoral Artery Stenosis, sponsored by Balton Sp.zo.o.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Planned enrollment
17th of 28
120 · median 220
Started
2024
with 2 others
No phase
16 of 31
4 open now
Registered
26th of 31
by date
Lead sponsor
3 of 31
Balton Sp.zo.o.

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 with no phase, and was the 26th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the performance and the safety of the PAK® DCB Catheter in the treatment of de novo and restenotic atherosclerotic lesions in the superficial femoral and/or popliteal arteries (SFA/PA) of patients with symptomatic peripheral artery disease (PAD).

The study enrolls patients who have been diagnosed with peripheral artery disease with stenosis of the superficial femoral or popliteal artery and are qualified for endovascular revascularization.

Lower extremity peripheral artery disease may be asymptomatic or may be accompanied by clinical symptoms due to restricted blood flow to the lower extremities.

The management of a patient diagnosed with peripheral arteriosclerosis is primarily aimed at reducing symptoms of limb ischemia and improving blood supply to the limb, as well as seeking to halt the progression of the disease.

Treatment of lower extremity atherosclerosis with percutaneous methods is a well-known minimally invasive and recommended treatment for lower extremity ischemia.

A maximum of 120 patients will be included in the study. All patients included in the study will receive treatment with the investigational device.

The study will use the PAK balloon catheter, which is CE certified and approved for the treatment of patients with peripheral vascular disease. That is, it is also used as standard outside the study. The test procedure with the study device is in accordance with its registration and instructions for use.

03

Conditions studied

  • Popliteal Artery Stenosis Above the Knee
  • Peripheral Artery Disease
  • Superficial Femoral Artery Stenosis

Keywords

  • Peripheral Artery Disease
  • Drug Coated Balloon
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Written of the patient to participate in the study.
  3. Symptoms of lower limb ischemia defined by Rutherford classification from 2 to 4.
  4. At least one de novo or restenotic lesion, in SFA and/or PA defined as a lesion with a proximal origin >10mm from SFA origin and a distal end above the knee joint (at least 3 cm above bottom of the femur- P1).
  5. Target Lesion >60% stenosis in the SFA or PA (based on angio-CT and/or confirmed in angiography).
  6. Target Lesion \<150 mm that consists of no more than two adjacent lesions ≤ 25mm apart and is able to be completely covered with inflation of single investigated PAK DCB (with minimum of >5mm proximal and distal margin.

    Note: Adjacent or tandem lesions must be treated as a single lesion.

  7. Reference Vessel Diameter (RVD) between 4.0 and 8.0mm and within treatment range of PAK® DCB to be used 1:1 at the target lesion.
  8. Angiographic evidence of distal run-off demonstrated by at least one patent tibial vessel without evidence of significant ≥50% angiographic stenosis from origin to ankle.
  9. In-flow vessel (both iliac and femoral) without significant ≥50% angiographic stenosis or successful treatment (≤30% residual stenosis with no complications) of a diseased in-flow vessel at least 30 days prior to the index procedure.

Note: treatment of contralateral iliac arteries is allowed.

Exclusion criteria

Exclusion Criteria:

  1. less than 2 years.
  2. Suspected or detected without completed treatment (not considered cured).
  3. Planned surgical or interventional procedures within 30 days after the study procedure.
  4. Known impaired renal function with ≤30 mL/min per 1.73 m2 and/or elevated serum creatinine > 2.5mg/dL or on dialysis.
  5. Active inflammatory process at the site of the planned puncture.
  6. Acute lower limb ischemia.
  7. Non-atherosclerotic lesion (e.g. vasculitis, dysplasia).
  8. Necessary concurrent non-target lesion interventions involving a re-entry device, atherectomy, laser, or ablation procedures, the use of a drug eluting stent, or treatment with any other drug coated balloon.
  9. Massive calcifications of the treated lesion (defined as angiographic evidence of dense calcification present on both sides of the vessel wall on two orthogonal views and that extends >50 continuous mm in length; reflective 3 or 4 on the PACSS scale https://doi.org/10.1002%2Fccd.25387).
  10. Angiographically confirmed presence of a thrombus in the target lesion.
  11. The target lesion requiring primary stenting.
  12. Presence of perforation, dissection (Type D or worse) or other injury in target vessel at time of enrollment.
  13. Previous bypass graft or stent at target vessel (must be greater than 20mm from target lesion), or iliac stent that cannot permit crossing by the treatment balloon within the introducer sheath Note: In-stent restenosis is not allowed.
  14. Gastrointestinal or any other major bleeding in the past three months.
  15. Known bleeding disorder or uncontrolled hypercoagulable disorder.
  16. Myocardial infarction or any stroke within 30 days prior to the procedure.
  17. Known intolerance to required medications (especially antiplatelets and heparin), contrast media (that cannot be adequately pre-medicated), nitinol or paclitaxel.
  18. Pregnant and childbearing age women not using effective .
  19. Participation in another study (before completing primary endpoint analysis) or previous enrollment to this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    PAK DCB catheter

    Peripheral revascularization procedure using a PAK DCB catheter covered with paclitaxel.

    Device: Paclitaxel Coated Peripheral Angioplasty Balloon Catheter

Interventions

  • DevicePaclitaxel Coated Peripheral Angioplasty Balloon Catheter

    Paclitaxel coated peripheral angioplasty balloon catheters are catheters of "over the wire" (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty.

    Also known as: PAK®

06

What researchers measure

Primary outcomes

  1. Safety - MAEs at 12 months

    Major Adverse Events (MAEs) at 12 months defined as the composite of: target-limb-related death, major amputation of the target limb and, re-intervention of the target limb.

    Time frame: 12 months

  2. Efficacy-PAK DCB Success at 12 months, defined as primary patency (PP)

    PAK DCB Success at 12 months, defined as primary patency (PP) in the absence of clinically driven bail-out stenting (CDBOS), as defined below. Subjects with no CDBOS will be assessed for PP for the purposes of determining True DCB Success. Clinically Driven Bail-Out Stenting (CDBOS): Stents are considered clinically driven when the angiographic core lab determines that a stent was placed after DCB use during the index procedure under the following conditions that were not resolved by prolonged balloon inflation: •Unresolved flow limiting dissection (Type E or F), OR •Residual lumen diameter stenosis \> 50% A subject with a CDBOS fails the True DCB success endpoint regardless of patency outcomes.

    Time frame: 12 months

  3. Primary Patency: Subjects who will achieve primary patency by a combination of duplex ultrasound review and no evidence of clinically driven target lesion revascularization (CD-TLR) prior to the study required 12-month DUS as defined below:

    Duplex Ultrasound Review: A patent target lesion shows a Peak Systolic Velocity Ratio (PSVR) less than 2.5 by the Duplex Ultrasound DUS core lab or Clinically Driven Target Lesion Revascularization CD-TLR: any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed that was considered clinically driven when both of the following conditions were met: Worsening clinical based on an ankle-brachial index (ABI) decrease≥20%or\>0.15 compared to maximum early postprocedure ABI or documented increase in Rutherford by at least one class if ABI change was unattainable. Angiographic core lab adjudication of the revascularization angiogram confirming that the target lesion prior to re-intervention demonstrated diameter stenosis \>50%.

    Time frame: 12 Month

Secondary outcomes

  1. Technical success rate.

    Technical success rate defined as successful balloon insertion, balloon inflation and removal.

    Time frame: During procedure

  2. Device success defined.

    Device success defined as ability to achieve optimal percutaneoustransluminal angioplasty (PTA) outcome (≤30% residual diameter stenosis in post-procedural angiography with no flow-limiting dissection at the target lesion).

    Time frame: During procedure

  3. Procedural success.

    Procedural success defined as device success with no major complications. (death, myocardial infarction, amputation, stroke).

    Time frame: Up to 3 days after index procedure

  4. Rate of CDBOS.

    Rate of Clinically Driven Bail-Out Stenting

    Time frame: Up to 3 days after index procedure

  5. Primary Patency at 12 months.

    Primary Patency at 12 months, defined as target lesion restenosis as determined by DUS (PSVR \< 2.5) and freedom from CD-TLR.

    Time frame: 12 months

  6. Secondary Patency at 12 months.

    Secondary Patency at 12 months defined by a PSVR less than 2.5 on DUS regardless of the need for TLR.

    Time frame: 12 months

  7. Freedom from clinically driven TLR at 30-day follow-up.

    Time frame: 30 days

  8. Freedom from clinically driven TLR at 6-month follow-up.

    Time frame: 6 months

  9. Freedom from clinically driven TLR at 12-month follow-up.

    Time frame: 12 months

  10. Freedom from TVR at 30-day follow-up.

    Time frame: 30 days

  11. Freedom from TVR at 6-month follow-up.

    Time frame: 6 months

  12. Freedom from TVR at 12-month follow-up.

    Time frame: 12 months

  13. All-cause mortality at 30-day follow-up.

    Time frame: 30 days

  14. All-cause mortality at 6-month follow-up.

    Time frame: 6 months

  15. All-cause mortality at 12-month follow-up.

    Time frame: 12 months

  16. Major amputation rate at 30-day follow-up.

    Time frame: 30 days

  17. Major amputation rate at 6-month follow-up.

    Time frame: 6 months

  18. Major amputation rate at 12-month follow-up.

    Time frame: 12 months

  19. Clinical improvement at 30-day follow-up.

    Clinical improvement at 30-day follow-up compared to the baseline, defined by Rutherford classification improved by at least one category if ABI improved by at least 20% or 0.15.

    Time frame: 30 days

  20. Clinical improvement at 6-month follow-up.

    Clinical improvement at 6-month follow-up compared to the baseline, defined by Rutherford classification improved by at least one category if ABI improved by at least 20% or 0.15.

    Time frame: 6 months

  21. Clinical improvement at 12-month follow-up.

    Clinical improvement at 12-month follow-up compared to the baseline, defined by Rutherford classification improved by at least one category if ABI improved by at least 20% or 0.15.

    Time frame: 12 months

07

Study locations

2 of 3 sites recruiting
  • Department of Vascular Surgery; Malopolska Cardiovascular Center; Polish-American Heart Clinics
    Chrzanów, Malopolska 32-500, Poland
    Recruiting
  • University Hospital Clinical Hospital No. 2 PUM in Szczecin, Department of General, Dental and Interventional Radiology
    Szczecin, Zachodniopomorskie 70-111, Poland
    Recruiting
    • Aleksander Falkowski, Prof. · Contactbakhis@hot.pl · (+48) 603945465
  • Vascular Surgery Teaching Unit CardioVascular Institute Hospital Clinic University of Barcelona
    Barcelona, 08036, Spain
    Not yet recruiting
08

References and documents

Publications

  • Buszman PP, Nowakowski P, Milewski K, Orlik B, Zurakowski A, Ludyga T, Polczyk F, Debinski M, Jelonek M, Kachel M, Gasior M, Granada JF, Kiesz RS, Buszman PE. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial. JACC Cardiovasc Interv. 2018 Dec 10;11(23):2436-2438. doi: 10.1016/j.jcin.2018.07.029. No abstract available. PubMed 30522679 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 24 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 16, 2024
StartActual
Sep 15, 2024
Primary completionEst.
Sep 15, 2026
CompletionEst.
Sep 15, 2026
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06734221
Lead sponsor
Balton Sp.zo.o.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Sep 15, 2024
Primary completion
Sep 15, 2026 (estimated)
Completion
Sep 15, 2026 (estimated)
Last update
Dec 16, 2024

Study contacts

Elżbieta Sojka
Contact
elzbieta.sojka@balton.pl
(+48) 22 597 44 43

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion